Product
NNC0385-0434 A
Aliases
NNC0385-0434 A 100 mg, NNC0385-0434 A 40 mg
2 clinical trials
2 indications
Indication
Atherosclerotic Cardiovascular DiseaseIndication
chronic kidney diseaseClinical trial
Dose Response and Safety of an Oral PCSK9i, NNC0385-0434, in Patients With Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk on Maximally Tolerated Statin Dose and Other Lipid-lowering Therapy Requiring Further LDL-C ReductionStatus: Completed, Estimated PCD: 2022-04-26
Clinical trial
Investigation of Pharmacokinetics, Safety and Tolerability of Oral NNC0385-0434 in Participants With Various Degrees of Impaired Renal Function and in Participants With Normal Renal FunctionStatus: Terminated, Estimated PCD: 2022-07-15